Contributors |
|
xix | |
Acknowledgment |
|
xxvii | |
Chapter 1 Microorganisms and antibiotic production |
|
1 | (6) |
|
|
|
|
Muhammad Sajid Hamid Akash |
|
|
|
1 | (1) |
|
|
1 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
|
2 | (1) |
|
1.5.1 Classification of antibiotics |
|
|
2 | (1) |
|
1.5.2 Mechanisms of antibiotic resistance |
|
|
3 | (1) |
|
1.5.3 Enzymatic inactivation |
|
|
3 | (1) |
|
|
3 | (1) |
|
1.5.5 Permeability changes |
|
|
3 | (1) |
|
1.6 Modifications of antimicrobial targets |
|
|
3 | (1) |
|
1.7 Production of antibiotics |
|
|
3 | (1) |
|
1.7.1 Natural production of antibiotics |
|
|
4 | (1) |
|
1.7.2 Semisynthetic production of antibiotics |
|
|
4 | (1) |
|
1.7.3 Synthetic production of antibiotics |
|
|
4 | (1) |
|
1.7.4 Industrial production of antibiotics |
|
|
4 | (1) |
|
1.7.5 Methods for increased production of antibiotics |
|
|
4 | (1) |
|
1.8 Stability of antimicrobial agents |
|
|
4 | (1) |
|
|
5 | (1) |
|
|
5 | (2) |
Chapter 2 Antibiotics and antimicrobial resistance: temporal and global trends in the environment |
|
7 | (21) |
|
|
|
|
|
Muhammad Sajid Hamid Akash |
|
|
|
7 | (1) |
|
2.2 Antimicrobial resistance |
|
|
7 | (14) |
|
|
8 | (3) |
|
2.2.2 Klebsiella pneumoniae |
|
|
11 | (4) |
|
2.2.3 Streptococcus pneumoniae |
|
|
15 | (2) |
|
2.2.4 Mycobacterium tuberculosis |
|
|
17 | (2) |
|
2.2.5 Pseudomonas aeruginosa |
|
|
19 | (1) |
|
2.2.6 Staphylococcus aureus |
|
|
20 | (1) |
|
|
21 | (1) |
|
|
22 | (6) |
Chapter 3 Antibiotics' presence in hospitals and associated wastes |
|
28 | (11) |
|
|
|
|
|
Muhammad Sajid Hamid Akash |
|
|
|
28 | (1) |
|
3.2 History of antibiotics |
|
|
29 | (1) |
|
3.3 Emerging trends of antibiotics in hospitals |
|
|
29 | (1) |
|
3.4 Prescribing pattern of antibiotics |
|
|
30 | (1) |
|
3.5 Antibiotics as quality metrics |
|
|
31 | (1) |
|
3.6 Measurement of antibiotic consumption |
|
|
32 | (1) |
|
3.7 Grams of antimicrobial therapy |
|
|
32 | (1) |
|
3.8 Cost of antimicrobial therapy |
|
|
32 | (1) |
|
3.9 Antimicrobial defined daily dose |
|
|
33 | (1) |
|
3.10 Antimicrobial days of therapy |
|
|
33 | (1) |
|
3.11 Antibiotic stewardship program |
|
|
33 | (1) |
|
3.12 Antibiotics and hospital-associated wastes |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
35 | (4) |
Chapter 4 Current trends of antimicrobials used in food animals and aquaculture |
|
39 | (31) |
|
|
|
|
|
|
|
|
|
|
|
Muhammad Sulman Ali Taseer |
|
|
|
|
|
39 | (1) |
|
4.2 Global consumption of antimicrobial trends in food animals |
|
|
40 | (1) |
|
4.3 Frequent trends of use of antimicrobials in the treatment of infectious and contagious diseases in food animals |
|
|
41 | (8) |
|
4.3.1 Use of antimicrobials in pigs |
|
|
41 | (1) |
|
4.3.2 Use of antimicrobials in goats and sheep |
|
|
41 | (2) |
|
4.3.3 Use of antimicrobials in cattle and cows |
|
|
43 | (1) |
|
4.3.4 Use of antimicrobials in horse |
|
|
43 | (2) |
|
4.3.5 Use of antimicrobials in poultry |
|
|
45 | (2) |
|
4.3.6 Use of antimicrobials in cats and dogs |
|
|
47 | (2) |
|
4.3.7 Use of antimicrobials in rabbits |
|
|
49 | (1) |
|
|
49 | (5) |
|
4.5 Global aquaculture trends |
|
|
54 | (2) |
|
|
56 | (1) |
|
4.7 Legislation concerning antimicrobial use in aquaculture |
|
|
57 | (1) |
|
4.8 Antimicrobial agents used in aquaculture |
|
|
57 | (1) |
|
4.9 Route of antimicrobial usage in aquaculture |
|
|
58 | (1) |
|
4.10 WHO list of antimicrobials used in aquaculture |
|
|
58 | (1) |
|
4.11 Unregulated use of antimicrobials in aquaculture |
|
|
58 | (1) |
|
4.12 Use of antimicrobials in fish |
|
|
59 | (1) |
|
4.13 Use of antimicrobials in crustaceans |
|
|
59 | (3) |
|
4.14 Use of antimicrobials in mollusks |
|
|
62 | (1) |
|
|
62 | (1) |
|
|
63 | (1) |
|
|
64 | (6) |
Chapter 5 Major natural sinks for harboring microorganisms with altered antibiotic resistance versus major human contributing sources of antibiotic resistance: a detailed insight |
|
70 | (29) |
|
|
|
|
|
|
|
|
|
70 | (13) |
|
5.1.1 Biological invasion is affected by climate change |
|
|
71 | (1) |
|
5.1.2 Importance of permafrost microbials among other microbes |
|
|
72 | (1) |
|
5.1.3 Microorganisms in cold environment |
|
|
72 | (1) |
|
5.1.4 Ancient microbes and impact of resurrected microbes |
|
|
72 | (1) |
|
5.1.5 Mechanisms of antibiotic resistance |
|
|
73 | (1) |
|
|
73 | (2) |
|
5.1.7 Glacial ice formation plus significance |
|
|
75 | (1) |
|
5.1.8 Glacial ice and the study of climate |
|
|
75 | (2) |
|
5.1.9 Preservation of life in ice |
|
|
77 | (1) |
|
5.1.10 Microorganisms in cold environments |
|
|
78 | (5) |
|
5.2 Resurrection of ecological research avenues |
|
|
83 | (3) |
|
5.2.1 Temporal adaptation of pathogen infectivity and host susceptibility |
|
|
83 | (2) |
|
5.2.2 Virulence in revitalized host-pathogen interactions |
|
|
85 | (1) |
|
5.3 Major man-made sources of antibiotics resistance |
|
|
86 | (4) |
|
|
86 | (1) |
|
5.3.2 Persistence of antibiotics in natural environment |
|
|
87 | (1) |
|
5.3.3 Environmental side effects |
|
|
88 | (1) |
|
5.3.4 Direct environmental side effects |
|
|
88 | (1) |
|
|
89 | (1) |
|
5.3.6 Events to reduce the discharge of antibiotic and antibiotic-resistance genes |
|
|
90 | (1) |
|
|
90 | (1) |
|
|
91 | (8) |
Chapter 6 Dissemination of antibiotic resistance in the environment |
|
99 | (18) |
|
|
|
|
|
|
|
99 | (1) |
|
6.2 Discovery and development of antibiotics |
|
|
100 | (1) |
|
6.3 Classification of antibacterial drugs |
|
|
101 | (2) |
|
6.3.1 Beta-lactams and fluoroquinolones |
|
|
102 | (1) |
|
|
102 | (1) |
|
6.3.3 Third-generation cephalosporins, cephamycins and carbapenems |
|
|
103 | (1) |
|
|
103 | (1) |
|
6.4 Antibiotic resistance development |
|
|
103 | (2) |
|
6.5 Causes of antibiotic resistance |
|
|
105 | (1) |
|
|
105 | (1) |
|
6.5.2 Incorrect prescription |
|
|
105 | (1) |
|
6.5.3 Use in other sectors |
|
|
105 | (1) |
|
|
106 | (1) |
|
6.6 Mechanism of antibiotic resistance |
|
|
106 | (4) |
|
6.6.1 Resistance mechanism against β-lactams |
|
|
106 | (1) |
|
|
106 | (1) |
|
6.6.3 Ambler molecular classification |
|
|
106 | (1) |
|
6.6.4 Extended-spectrum beta-lactamases |
|
|
107 | (1) |
|
|
107 | (1) |
|
|
107 | (1) |
|
|
107 | (1) |
|
|
108 | (1) |
|
6.6.9 Target site alteration |
|
|
108 | (1) |
|
6.6.10 Reduced permeability |
|
|
108 | (1) |
|
|
108 | (1) |
|
6.6.12 Resistance mechanism against fluoroquinolones |
|
|
108 | (1) |
|
6.6.13 Mutations in target |
|
|
109 | (1) |
|
6.6.14 Resistance mediated by plasmid |
|
|
109 | (1) |
|
6.6.15 Chromosome-mediated resistance |
|
|
109 | (1) |
|
6.6.16 Antibiotic resistance consequences |
|
|
109 | (1) |
|
6.7 Antibiotic-resistant genes |
|
|
110 | (1) |
|
6.8 Dissemination of antibiotic-resistant genes in environment |
|
|
110 | (4) |
|
|
110 | (1) |
|
|
110 | (2) |
|
|
112 | (1) |
|
|
112 | (2) |
|
6.8.5 Pathways for dissemination of ARGs in environment |
|
|
114 | (1) |
|
|
114 | (3) |
Chapter 7 Long-range transport of antibiotics and AMR/ARGs |
|
117 | (9) |
|
|
|
Muhammad Umer Farooq Awan |
|
|
|
|
117 | (1) |
|
7.2 Historical perspective of antibiotics |
|
|
118 | (1) |
|
7.3 Invisible organisms causing diseases |
|
|
118 | (1) |
|
7.4 Phylogenetic analysis of antibiotic resistance genes |
|
|
119 | (1) |
|
7.5 Antibiotic resistance |
|
|
119 | (1) |
|
7.6 Distribution of antibiotic resistance genes in environment |
|
|
120 | (1) |
|
7.7 Antimicrobial resistance in environment |
|
|
121 | (1) |
|
7.8 Need for antimicrobial environmental protection |
|
|
121 | (2) |
|
7.8.1 Mechanisms of antibiotic resistance |
|
|
122 | (1) |
|
|
123 | (3) |
Chapter 8 Antibiotics and antimicrobial resistance mechanism of entry in the environment |
|
126 | (12) |
|
|
8.1 General aspects of antibiotics use |
|
|
126 | (3) |
|
8.1.1 Introduction to the term "antibiotic use" |
|
|
126 | (1) |
|
8.1.2 Antibiotic resistance to bacteria |
|
|
127 | (1) |
|
8.1.3 Correct use of antibiotics |
|
|
127 | (2) |
|
8.2 General pathways of introduction of antibiotics in environment |
|
|
129 | (2) |
|
8.2.1 Water/soil environment antibiotics exposure |
|
|
130 | (1) |
|
8.2.2 Water/sludge environment antibiotics exposure |
|
|
131 | (1) |
|
8.3 Antimicrobial resistance |
|
|
131 | (3) |
|
8.3.1 Bacterial resistance mechanism and control |
|
|
132 | (1) |
|
|
133 | (1) |
|
|
134 | (1) |
|
|
134 | (1) |
|
|
135 | (3) |
Chapter 9 Antibiotics, AMRs, and ARGs: fate in the environment |
|
138 | (17) |
|
|
|
|
138 | (1) |
|
9.2 Estimation of risk of developing antibiotic resistance |
|
|
138 | (2) |
|
9.3 Environmental and human risk |
|
|
140 | (1) |
|
9.4 Fate of antibiotics in soil |
|
|
141 | (1) |
|
9.5 Fate of antibiotics in wastewater |
|
|
142 | (2) |
|
9.6 Fate of antibiotics in plants |
|
|
144 | (1) |
|
9.7 Uptake of antibiotics by plants and translocation into tissues |
|
|
145 | (1) |
|
9.8 Fate of AMR/ARBs and ARGs |
|
|
146 | (1) |
|
9.9 Factors responsible for the fate of ARB and ARGs |
|
|
147 | (1) |
|
9.10 Antibiotic resistant genes |
|
|
147 | (1) |
|
9.11 Facilitation in spread of resistant genes through integrons |
|
|
148 | (2) |
|
|
150 | (1) |
|
|
151 | (4) |
Chapter 10 On the edge of a precipice: the global emergence and dissemination of plasmid-borne mcr genes that confer resistance to colistin, a last-resort antibiotic |
|
155 | (28) |
|
|
|
|
|
10.1 A brief history of colistin |
|
|
155 | (1) |
|
10.2 Colistin use in animal farming practices |
|
|
156 | (1) |
|
10.3 Emergence of mobile colistin resistance on the global stage |
|
|
157 | (16) |
|
|
157 | (2) |
|
10.3.2 Middle East and North Africa (MENA) Region |
|
|
159 | (4) |
|
|
163 | (7) |
|
10.3.4 Africa: South Africa |
|
|
170 | (1) |
|
|
170 | (3) |
|
|
173 | (1) |
|
10.4 Stepping away from the precipice: Conclusions and recommendations |
|
|
173 | (1) |
|
|
174 | (9) |
Chapter 11 Uptake mechanism of antibiotics in plants |
|
183 | (6) |
|
|
|
|
|
|
|
|
|
183 | (1) |
|
11.2 Genes related to antibiotic resistance developed in plant endosymbionts |
|
|
184 | (1) |
|
11.3 Effects of antibiotic exposure on endosymbionts |
|
|
184 | (1) |
|
11.4 Types of antibiotics in soil |
|
|
185 | (1) |
|
11.4.1 New class of antibiotics |
|
|
185 | (1) |
|
11.5 Consumption of antimicrobial agents from soil through animal dung |
|
|
185 | (1) |
|
11.6 Mechanism of uptake of antimicrobial agents by plants |
|
|
186 | (1) |
|
11.7 Animal manure, a source of antibiotics |
|
|
186 | (1) |
|
11.8 Factors affecting uptake mechanisms of antibiotics in plants |
|
|
186 | (1) |
|
11.9 Effect of antibiotic exposure on endosymbionts |
|
|
187 | (1) |
|
11.10 Role of antibiotic resistant endophytic bacteria in plant uptake |
|
|
187 | (1) |
|
|
187 | (2) |
Chapter 12 Modeling the spread of antibiotics and AMR/ARGs in soil |
|
189 | (6) |
|
|
|
189 | (1) |
|
12.2 Fate and degradation of antibiotics in soil |
|
|
190 | (1) |
|
12.3 Modeling of antibiotic resistance genes in soil |
|
|
191 | (1) |
|
|
192 | (1) |
|
|
192 | (2) |
|
|
194 | (1) |
Chapter 13 Metagenomics and methods development for the determination of antibiotics and AMR/ARGS |
|
195 | (11) |
|
|
|
|
|
195 | (1) |
|
13.2 Antimicrobial analysis by the metagenomic method |
|
|
196 | (1) |
|
13.3 Advances in metagenomic analysis for evaluating antimicrobial resistance |
|
|
197 | (5) |
|
13.3.1 Human microbiome analysis |
|
|
197 | (1) |
|
13.3.2 Pathogenomics analysis |
|
|
198 | (1) |
|
|
198 | (1) |
|
13.3.4 Marine environment analysis |
|
|
199 | (1) |
|
13.3.5 Wastewater treatment effluents analysis |
|
|
200 | (1) |
|
13.3.6 Drinking water analysis |
|
|
201 | (1) |
|
13.3.7 Analysis of veterinary and agricultural sources |
|
|
201 | (1) |
|
|
202 | (1) |
|
|
202 | (4) |
Chapter 14 Global trends in ARGs measured by HT-qPCR platforms |
|
206 | (17) |
|
|
|
|
|
|
|
206 | (6) |
|
14.1.1 Use of HT-qPCR for measuring AMR in aquatic environments |
|
|
208 | (2) |
|
14.1.2 Wastewater treatment plants |
|
|
210 | (1) |
|
|
211 | (1) |
|
14.2 Use of HT-qPCR for measuring AMR in soil |
|
|
212 | (3) |
|
14.3 Use of HT-qPCR for measuring AMR in gut microbiomes |
|
|
215 | (1) |
|
|
216 | (1) |
|
|
216 | (7) |
Chapter 15 Databases, multiplexed PCR, and next-generation sequencing technologies for tracking AMR genes in the environment |
|
223 | (11) |
|
|
|
|
Muhammad Sajid Hamid Akash |
|
|
|
223 | (1) |
|
15.2 Databases of antimicrobial resistance genes in the environment |
|
|
224 | (2) |
|
15.3 Techniques used for tracking the AMR genes in the environment |
|
|
226 | (2) |
|
15.3.1 Multiplex polymerase chain reaction |
|
|
226 | (2) |
|
15.4 Next-generation sequencing |
|
|
228 | (1) |
|
|
229 | (1) |
|
|
230 | (4) |
Chapter 16 Toxicity of antibiotics |
|
234 | (19) |
|
|
|
Muhammad Sajid Hamid Akash |
|
|
|
234 | (1) |
|
16.2 History of antibiotic discovery |
|
|
234 | (1) |
|
|
235 | (1) |
|
16.4 Toxicity of antibacterial |
|
|
235 | (15) |
|
16.4.1 Toxicity of beta-lactam antibiotics |
|
|
235 | (1) |
|
16.4.2 Hypersensitivity reactions |
|
|
235 | (1) |
|
16.4.3 Other toxicities of β-lactam antibiotics |
|
|
236 | (2) |
|
16.4.4 Toxicity of protein synthesis inhibitors |
|
|
238 | (2) |
|
16.4.5 Toxicity of tetracyclines |
|
|
240 | (1) |
|
16.4.6 Toxicity of macrolides |
|
|
240 | (1) |
|
16.4.7 Toxicity of chloramphenicol |
|
|
241 | (1) |
|
16.4.8 Toxicity of clindamycin and vancomycin |
|
|
242 | (1) |
|
16.4.9 Toxicity of streptogramins |
|
|
242 | (1) |
|
16.4.10 Toxicity of linezolid |
|
|
242 | (1) |
|
16.4.11 Toxicity of folic acid synthesis inhibitors |
|
|
243 | (1) |
|
16.4.12 Hypersensitivity reactions |
|
|
243 | (2) |
|
16.4.13 Other side effects |
|
|
245 | (1) |
|
16.4.14 Toxicity of DNA synthesis inhibitors |
|
|
245 | (1) |
|
16.4.15 Toxicity of antiviral agents |
|
|
246 | (1) |
|
16.4.16 Toxicity of antiretroviral agents |
|
|
246 | (3) |
|
16.4.17 Toxicity of antiprotozoal chemotherapy |
|
|
249 | (1) |
|
16.5 Toxicity of antifungal agents |
|
|
250 | (1) |
|
|
250 | (1) |
|
|
250 | (1) |
|
16.5.3 Imidazoles and triazoles |
|
|
250 | (1) |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
251 | (1) |
|
|
251 | (2) |
Chapter 17 Carbapenems and Pseudomonas aeruginosa: mechanisms and epidemiology |
|
253 | (16) |
|
|
|
|
|
|
253 | (1) |
|
|
253 | (1) |
|
17.2.1 Characteristics of P aeruginosa |
|
|
254 | (1) |
|
17.3 Pathogenesis of P aeruginosa |
|
|
254 | (2) |
|
|
255 | (1) |
|
|
256 | (1) |
|
17.5 Antibiotic resistance |
|
|
257 | (1) |
|
17.6 Antibiotic resistance mechanisms in P. aeruginosa |
|
|
258 | (1) |
|
17.7 Resistance to carbapenems |
|
|
259 | (2) |
|
17.8 Resistance to colistin |
|
|
261 | (3) |
|
|
264 | (1) |
|
|
264 | (1) |
|
|
264 | (5) |
Chapter 18 Environmental and public health effects of antibiotics and AMR/ARGs |
|
269 | (23) |
|
|
|
|
18.1 Introduction to antimicrobial resistance in the environment |
|
|
269 | (1) |
|
18.2 Antibiotic resistance in the environment |
|
|
270 | (1) |
|
18.3 Global antimicrobial-resistance action plan |
|
|
270 | (1) |
|
18.4 Food and Agriculture Organization antimicrobial resistance development framework |
|
|
271 | (1) |
|
18.5 Antimicrobial resistance, National Action Plan, Pakistan |
|
|
271 | (1) |
|
18.6 Key drivers of AMR/ARGs in the environment |
|
|
272 | (2) |
|
18.6.1 Horizontal gene transfer |
|
|
272 | (1) |
|
18.6.2 Soil-borne resistance |
|
|
273 | (1) |
|
|
273 | (1) |
|
18.6.4 Wastewater and sludge |
|
|
274 | (1) |
|
18.7 Environmental pathways for antibiotic resistance |
|
|
274 | (3) |
|
18.7.1 Spread of antimicrobial resistance via municipal and industrial water |
|
|
274 | (1) |
|
18.7.2 Transmission of antimicrobial resistance via livestock |
|
|
275 | (1) |
|
18.7.3 Spreading of antibiotic resistance via gray water and recycled water |
|
|
276 | (1) |
|
18.8 Ways to reduce antimicrobial resistance in the environment |
|
|
277 | (2) |
|
18.8.1 Minimization of antibiotic use in humans, animals, and plants |
|
|
277 | (1) |
|
18.8.2 Efficient treatment of wastes to eliminate the antimicrobial residues (urban, industrial, agricultural, hospitals, solid and liquid waste) |
|
|
278 | (1) |
|
18.8.3 Efforts to minimize the use of antibiotics by improving hygiene practices |
|
|
278 | (1) |
|
18.8.4 Spreading awareness and educating the masses |
|
|
279 | (1) |
|
18.9 Ethics regarding the use of antibiotics in the environment |
|
|
279 | (1) |
|
18.10 Ethical facets of antibiotics resistance |
|
|
280 | (1) |
|
18.10.1 Ethics regarding antibiotic use for controlling infectious diseases |
|
|
280 | (1) |
|
18.10.2 Ethics regarding the fair distribution of global resources |
|
|
280 | (1) |
|
18.10.3 Ethics regarding the use of antibiotics in veterinary practices |
|
|
281 | (1) |
|
18.10.4 Ethics regarding the use of antibiotics in environment |
|
|
281 | (1) |
|
18.11 Alternative therapies to eradicate the AMR/ARGs |
|
|
281 | (2) |
|
18.11.1 Environmental nanotechnology |
|
|
281 | (1) |
|
18.11.2 Antimicrobial peptides |
|
|
282 | (1) |
|
18.11.3 Bacteriophage therapy |
|
|
282 | (1) |
|
18.11.4 CRISPR approaches to environmental AMR |
|
|
283 | (1) |
|
18.12 Public health and AMR/ARGs |
|
|
283 | (2) |
|
18.12.1 AMR/ARGs, a serious public health problem |
|
|
283 | (1) |
|
18.12.2 Primary and secondary AMR |
|
|
283 | (1) |
|
18.12.3 Diseases with potential of antimicrobial resistance |
|
|
284 | (1) |
|
18.12.4 Preventive measures for reduction of AMR |
|
|
285 | (1) |
|
|
285 | (1) |
|
|
285 | (6) |
|
|
291 | (1) |
Chapter 19 Antibiotics resistance mechanism |
|
292 | (21) |
|
|
|
|
|
|
19.1 What are antibiotics? |
|
|
292 | (2) |
|
|
292 | (1) |
|
19.1.2 How antibiotics work |
|
|
293 | (1) |
|
19.1.3 Broad-spectrum antibiotics |
|
|
294 | (1) |
|
19.1.4 Vaccines block diseases |
|
|
294 | (1) |
|
19.1.5 Example of malaria transmission blocking vaccines |
|
|
294 | (1) |
|
19.2 Attack and nature of pathogens |
|
|
294 | (3) |
|
19.3 Mechanism of action of antibiotics |
|
|
297 | (2) |
|
19.3.1 Impairment synthesis of cell wall |
|
|
297 | (1) |
|
19.3.2 Impairment of protein biosynthesis |
|
|
297 | (1) |
|
19.3.3 Impairment of DNA replication |
|
|
298 | (1) |
|
19.3.4 Alteration of cell membrane |
|
|
298 | (1) |
|
19.3.5 Antimetabolite activity |
|
|
299 | (1) |
|
|
299 | (1) |
|
19.5 Toxicity of antibiotics |
|
|
300 | (1) |
|
19.6 Emergence of antibiotic resistance |
|
|
300 | (5) |
|
19.6.1 Pathway toward self-medication |
|
|
301 | (1) |
|
19.6.2 Genetic mutations among bacteria and microorganisms |
|
|
301 | (2) |
|
19.6.3 Phenotypic resistance to antibiotics |
|
|
303 | (1) |
|
19.6.4 Development of resistance |
|
|
303 | (1) |
|
19.6.5 Enzymatic degradation of antibacterial drug |
|
|
303 | (1) |
|
19.6.6 Alteration of bacterial proteins that are antimicrobial target |
|
|
303 | (1) |
|
19.6.7 Change in the membrane permeability |
|
|
304 | (1) |
|
|
304 | (1) |
|
19.6.9 Modify or bypass the antibiotic's target |
|
|
304 | (1) |
|
19.7 Transfer of resistant genes among pathogens |
|
|
305 | (1) |
|
19.7.1 Mechanisms of horizontal gene transfer |
|
|
305 | (1) |
|
19.8 Antibiotics resistant bacterial infections |
|
|
305 | (3) |
|
19.8.1 Methicillin-resistant Staphylococcus aureus |
|
|
305 | (1) |
|
19.8.2 Vancomycin-resistant enterococci |
|
|
306 | (1) |
|
19.8.3 Drug-resistant streptococcus pneumoniae |
|
|
306 | (1) |
|
19.8.4 Drug-resistant mycobacterium tuberculosis |
|
|
306 | (1) |
|
19.8.5 Carbapenem-resistant enterobacteriaceae |
|
|
307 | (1) |
|
19.8.6 Multidrug-resistant Pseudomonas aeruginosa |
|
|
307 | (1) |
|
19.8.7 Multi-drug-resistant Acinetobacter baumannii infection |
|
|
307 | (1) |
|
19.8.8 ESBL producing enterobacteriaceae resistance |
|
|
307 | (1) |
|
19.8.9 Antibiotic-resistant Neisseria gonorrhoeae |
|
|
308 | (1) |
|
|
308 | (1) |
|
19.9.1 Gene target medications to avoid antibiotic resistance |
|
|
308 | (1) |
|
19.9.2 Continuous change in nature of antibiotics |
|
|
309 | (1) |
|
19.9.3 RNA-mediated gene silencing of pathogens |
|
|
309 | (1) |
|
|
309 | (1) |
|
|
309 | (4) |
Chapter 20 Microbial risk assessment and antimicrobial resistance |
|
313 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
313 | (2) |
|
20.2 Risk assessment of antimicrobial resistance in food safety |
|
|
315 | (3) |
|
20.2.1 Assessment of exposure |
|
|
316 | (2) |
|
20.3 Antimicrobial resistance risk assessment in water and sanitation |
|
|
318 | (1) |
|
20.3.1 Wastewater treatment plants |
|
|
318 | (1) |
|
20.3.2 Water treatment techniques and management strategies as barriers for AMR spreading |
|
|
319 | (1) |
|
20.4 Risk assessment of antibiotic resistance transmission through environment to humans |
|
|
319 | (4) |
|
20.4.1 Transmission and entry of antibiotic-resistant bacteria to humans |
|
|
319 | (1) |
|
20.4.2 Important steps for risk assessment |
|
|
319 | (4) |
|
20.5 Antimicrobial resistance risk assessment in environment |
|
|
323 | (1) |
|
20.5.1 Environmental transmission pathways |
|
|
323 | (1) |
|
20.5.2 Risk analysis process |
|
|
323 | (1) |
|
20.6 Methods and management of risk assessment in relation to antimicrobial resistance |
|
|
324 | (1) |
|
20.6.1 Policy of risk regulation |
|
|
324 | (1) |
|
20.6.2 Components of risk management |
|
|
324 | (1) |
|
20.7 Risk evaluation and regulation |
|
|
325 | (3) |
|
|
325 | (3) |
|
|
328 | (1) |
|
|
328 | (1) |
|
|
328 | (3) |
Chapter 21 Environmental risk assessment of antibiotics and AMR/ARGs |
|
331 | (19) |
|
|
|
|
|
|
|
|
|
331 | (1) |
|
21.2 Classification of antibiotics |
|
|
332 | (3) |
|
21.3 Inhibitors of cell wall synthesis |
|
|
335 | (1) |
|
|
335 | (1) |
|
|
335 | (1) |
|
|
335 | (1) |
|
21.4 Inhibitors for DNA synthesis |
|
|
335 | (1) |
|
|
335 | (1) |
|
|
335 | (1) |
|
21.5 Inhibitors for RNA synthesis |
|
|
336 | (1) |
|
|
336 | (1) |
|
|
336 | (1) |
|
21.6 Inhibitors for protein synthesis |
|
|
336 | (1) |
|
|
336 | (1) |
|
|
336 | (1) |
|
|
336 | (1) |
|
|
337 | (1) |
|
|
337 | (1) |
|
|
337 | (1) |
|
21.7 Intercalators (DNA replication) |
|
|
337 | (1) |
|
|
337 | (1) |
|
21.8 Anaerobic DNA inhibitors |
|
|
337 | (1) |
|
|
337 | (1) |
|
|
337 | (1) |
|
21.9 Risk assessment of antibiotics |
|
|
338 | (2) |
|
|
338 | (1) |
|
21.9.2 Terrestrial or soil risk |
|
|
338 | (1) |
|
|
339 | (1) |
|
21.10 Antimicrobial resistance genes |
|
|
340 | (4) |
|
21.10.1 Classification of antibiotic resistance genes and their subtypes |
|
|
340 | (1) |
|
21.10.2 Human exposure to ARGs at coastal site |
|
|
340 | (1) |
|
21.10.3 ARGs from sludge, WWTPs and added to soil organic fertilizer |
|
|
341 | (2) |
|
21.10.4 Mode of ARGs spread within microbial communities in soil |
|
|
343 | (1) |
|
21.10.5 Spread of ARGs within bacterial communities |
|
|
343 | (1) |
|
21.10.6 Reported life loss and recent protective measures for AMR |
|
|
344 | (1) |
|
|
344 | (6) |
Chapter 22 Nanobiotechnology-based drug delivery strategy as a potential weapon against multiple drug-resistant pathogens |
|
350 | (19) |
|
|
|
|
|
|
|
|
|
|
|
|
350 | (1) |
|
22.2 Nanostructures and nanomaterials |
|
|
351 | (7) |
|
22.2.1 Silver (Ag) nanoparticles |
|
|
351 | (2) |
|
22.2.2 Gold nanoparticles (AuNPs) |
|
|
353 | (1) |
|
22.2.3 Copper oxide nanoparticles (CuO NPs) |
|
|
353 | (1) |
|
22.2.4 Iron-containing nanoparticles (Fe3O4 NPs) |
|
|
354 | (1) |
|
22.2.5 Carbon-based nanoparticles |
|
|
354 | (1) |
|
22.2.6 Magnetic nanoparticles |
|
|
355 | (1) |
|
22.2.7 Chitosan nanoparticles |
|
|
356 | (2) |
|
22.3 Biological compatibility of nanoparticles |
|
|
358 | (1) |
|
22.3.1 Hemocompatibility and histocompatibility of nanoparticles |
|
|
358 | (1) |
|
22.4 In vivo and in vitro experimental analysis |
|
|
358 | (1) |
|
22.5 Synthesis and characterization of nanoparticles |
|
|
359 | (1) |
|
22.6 Drug delivery mechanisms |
|
|
360 | (1) |
|
22.7 Nanoparticles' mechanisms for drug targeting |
|
|
360 | (2) |
|
|
360 | (2) |
|
22.7.2 Surface charge/particle charge |
|
|
362 | (1) |
|
|
362 | (1) |
|
22.7.4 Surface modifications and cell targeting |
|
|
362 | (1) |
|
22.8 Cellular uptake mechanisms |
|
|
362 | (1) |
|
|
362 | (1) |
|
|
363 | (1) |
|
|
363 | (1) |
|
|
364 | (5) |
Chapter 23 Treatment technologies and management options of antibiotics and AMR/ARGs |
|
369 | (26) |
|
|
|
|
|
|
|
|
|
|
|
369 | (1) |
|
23.2 Antibiotics and antimicrobial resistance |
|
|
370 | (2) |
|
23.3 Environmental implications of antibiotics and AMR/ARGs |
|
|
372 | (1) |
|
23.4 Treatment technologies |
|
|
372 | (13) |
|
23.4.1 Biological methods |
|
|
372 | (5) |
|
|
377 | (3) |
|
|
380 | (4) |
|
23.4.4 Integrated treatment system |
|
|
384 | (1) |
|
23.5 Management options to minimize antibiotic and AMR release |
|
|
385 | (1) |
|
|
386 | (1) |
|
|
386 | (9) |
Index |
|
395 | |